Literature DB >> 28129461

Bullous pemphigoid associated with nivolumab, a programmed cell death 1 protein inhibitor.

C W Kwon1, A S Land1, B R Smoller1,2, G Scott1,2, L A Beck1, M G Mercurio1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28129461     DOI： 10.1111/jdv.14143

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  7 in total

Review 1.  Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors.

Authors:  Jennifer Choi; Ronald Anderson; Ada Blidner; Tim Cooksley; Michael Dougan; Ilya Glezerman; Pamela Ginex; Monica Girotra; Dipti Gupta; Douglas Johnson; Vickie R Shannon; Maria Suarez-Almazor; Bernardo L Rapoport; Mario E Lacouture
Journal:  Support Care Cancer       Date:  2020-08-27       Impact factor: 3.603

Review 2.  Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.

Authors:  Samantha R Ellis; Aren T Vierra; Jillian W Millsop; Mario E Lacouture; Maija Kiuru
Journal:  J Am Acad Dermatol       Date:  2020-04-29       Impact factor: 11.527

3.  Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature.

Authors:  Coralie Zumelzu; Marina Alexandre; Christelle Le Roux; Patricia Weber; Alexis Guyot; Annie Levy; Françoise Aucouturier; Sabine Mignot-Grootenboer; Frédéric Caux; Eve Maubec; Catherine Prost-Squarcioni
Journal:  Front Med (Lausanne)       Date:  2018-09-27

4.  Localized bullous pemphigoid in a melanoma patient with dual exposure to PD-1 checkpoint inhibition and radiation therapy.

Authors:  Kelsey Hirotsu; Albert S Chiou; Audris Chiang; Jinah Kim; Bernice Y Kwong; Silvina Pugliese
Journal:  JAAD Case Rep       Date:  2017-08-30

Review 5.  A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management.

Authors:  Adriana T Lopez; Larisa Geskin
Journal:  Oncologist       Date:  2018-07-17

6.  Recurrence of Pemphigus Vulgaris Under Nivolumab Therapy.

Authors:  Sebastian Krammer; Christian Krammer; Suzanna Salzer; Işin Sinem Bağci; Lars E French; Daniela Hartmann
Journal:  Front Med (Lausanne)       Date:  2019-11-12

7.  Bullous Pemphigoid in Patients Receiving Immune-Checkpoint Inhibitors and Psoriatic Patients-Focus on Clinical and Histopathological Variation.

Authors:  Dennis Niebel; Dagmar Wilsmann-Theis; Thomas Bieber; Mark Berneburg; Joerg Wenzel; Christine Braegelmann
Journal:  Dermatopathology (Basel)       Date:  2022-03-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.